These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 15566355

  • 1. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS.
    Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
    [Abstract] [Full Text] [Related]

  • 2. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 3. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 4. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR.
    Semin Oncol; 2003 Apr 01; 30(2):300-4. PubMed ID: 12720157
    [Abstract] [Full Text] [Related]

  • 5. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K.
    Clin Cancer Res; 2003 Sep 15; 9(11):4267-73. PubMed ID: 14519654
    [Abstract] [Full Text] [Related]

  • 6. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 7. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 24; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma.
    Klasa RJ.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):25-31. PubMed ID: 15651174
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.
    Nichols GL, Stein CA.
    Semin Oncol; 2003 Apr 01; 30(2):297-9. PubMed ID: 12720156
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
    Yan JS, Chen XY, Li WP, Yang Y, Song ZL.
    Ai Zheng; 2009 Feb 01; 28(2):181-3. PubMed ID: 19550134
    [Abstract] [Full Text] [Related]

  • 19. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A.
    Clin Cancer Res; 2006 May 01; 12(9):2902-11. PubMed ID: 16675587
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.